novo nordisk oral glp 1 Wins EU Approval for First GLP-1 Weight-Loss Drug Wegovy Novo Nordisk strikes $2.1bn oral

Viking Therapeutics stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisks Wegovy and Eli Lillys Zepbound.

Results Twenty-eight RCTs were ultimately included for analysis, involving a total of 77,485 participants

These milestones will redefine how obesity care is delivered, marking a turning point that will shape the markets trajectory for 2026 and the years to come

When linagliptin was co-administered with a GIP-antagonising antibody, the impact of linagliptin was partially blunted in wild-type mice and was fully blocked in GcgRANull mice

If youre on a GLP-1&nbsp

A comprehensive program of nutritional and lifestyle counseling is critical to maximize overall efficacy and improve cost-effectiveness of GLP-1s for obesity.